-
2
-
-
0042198675
-
B-type natriuretic peptide in cardiovascular medicine
-
de Lemomos J.A., McGuire D.K., and Drazner M.H. B-type natriuretic peptide in cardiovascular medicine. Lancet 362 (2003) 316-322
-
(2003)
Lancet
, vol.362
, pp. 316-322
-
-
de Lemomos, J.A.1
McGuire, D.K.2
Drazner, M.H.3
-
3
-
-
0034702908
-
Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension
-
Nagaya N., Nishikimi T., Uematsu E., Satoh T., Kyotani S., Sakamaki F., Kakishita M., Fukushima K., Okano Y., Nakanishi N., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 102 (2000) 865-870
-
(2000)
Circulation
, vol.102
, pp. 865-870
-
-
Nagaya, N.1
Nishikimi, T.2
Uematsu, E.3
Satoh, T.4
Kyotani, S.5
Sakamaki, F.6
Kakishita, M.7
Fukushima, K.8
Okano, Y.9
Nakanishi, N.10
-
4
-
-
0023615359
-
Primary pulmonary hypertension. a national prospective study
-
Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., Koerner S.K., et al. Primary pulmonary hypertension. a national prospective study. Ann Intern Med 107 (1987) 216-223
-
(1987)
Ann Intern Med
, vol.107
, pp. 216-223
-
-
Rich, S.1
Dantzker, D.R.2
Ayres, S.M.3
Bergofsky, E.H.4
Brundage, B.H.5
Detre, K.M.6
Fishman, A.P.7
Goldring, R.M.8
Groves, B.M.9
Koerner, S.K.10
-
5
-
-
0029993602
-
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
-
Olschewski H., Walmrath D., Schermuly, Ghofrani A., Grimminger E., and Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124 (1996) 820-824
-
(1996)
Ann Intern Med
, vol.124
, pp. 820-824
-
-
Olschewski, H.1
Walmrath, D.2
Schermuly3
Ghofrani, A.4
Grimminger, E.5
Seeger, W.6
-
6
-
-
0035163117
-
Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism
-
Tulevski I.I., Hirsch A., Sanson B.-J., Romkes H., van der Wall E.E., van Veldhuisen D.J., Büller H.R., and Mulder B.J.M. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 86 (2001) 1193-1196
-
(2001)
Thromb Haemost
, vol.86
, pp. 1193-1196
-
-
Tulevski, I.I.1
Hirsch, A.2
Sanson, B.-J.3
Romkes, H.4
van der Wall, E.E.5
van Veldhuisen, D.J.6
Büller, H.R.7
Mulder, B.J.M.8
-
7
-
-
0036300747
-
Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thromboendarterectomy
-
Nagaya N., Ando M., Oya H., and Nakanishi N. Plasma brain natriuretic peptide as a non-invasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 74 (2002) 180-184
-
(2002)
Ann Thorac Surg
, vol.74
, pp. 180-184
-
-
Nagaya, N.1
Ando, M.2
Oya, H.3
Nakanishi, N.4
-
8
-
-
0242319767
-
Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension
-
Mukerjee D., Yap L.B., Holmes A.M., Nair D., Ayrton P., Black C.M., and Coghlan J.G. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 97 (2003) 1230-1236
-
(2003)
Respir Med
, vol.97
, pp. 1230-1236
-
-
Mukerjee, D.1
Yap, L.B.2
Holmes, A.M.3
Nair, D.4
Ayrton, P.5
Black, C.M.6
Coghlan, J.G.7
-
9
-
-
3543046555
-
Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension
-
Leuchte N.N., Neurohr C., Baumgartner R.A., Holzapfel M., Giehrl W., Vogeser M., and Behr J. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 170 (2004) 360-365
-
(2004)
Am J Respir Crit Care Med
, vol.170
, pp. 360-365
-
-
Leuchte, N.N.1
Neurohr, C.2
Baumgartner, R.A.3
Holzapfel, M.4
Giehrl, W.5
Vogeser, M.6
Behr, J.7
-
10
-
-
3142777629
-
Prognosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines
-
McLaughlin V.V., Presberg K.W., Doyle R.L., Abman S.H., McCrory D.C., Fortin T., and Ahern G. Prognosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 78S-92S
-
(2004)
Chest
, vol.126
-
-
McLaughlin, V.V.1
Presberg, K.W.2
Doyle, R.L.3
Abman, S.H.4
McCrory, D.C.5
Fortin, T.6
Ahern, G.7
-
11
-
-
0037118681
-
Assessment of survival in patients with primary pulmonary hypertension. importance of cardiopulmonary exercise testing
-
Wensel R., Opitz C.F., Anker S.D., Winkler J., Hoffken G., Kleber F.X., Sharma R., Hummel M., Hetzer R., and Ewert R. Assessment of survival in patients with primary pulmonary hypertension. importance of cardiopulmonary exercise testing. Circulation 106 (2002) 319-324
-
(2002)
Circulation
, vol.106
, pp. 319-324
-
-
Wensel, R.1
Opitz, C.F.2
Anker, S.D.3
Winkler, J.4
Hoffken, G.5
Kleber, F.X.6
Sharma, R.7
Hummel, M.8
Hetzer, R.9
Ewert, R.10
-
12
-
-
0026632785
-
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
-
Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
-
(1992)
N Engl J Med
, vol.327
, pp. 76-81
-
-
Rich, S.1
Kaufmann, E.2
Levy, P.S.3
|